Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab ( (GMAB) ) just unveiled an announcement.
Genmab A/S has provided an update on its ongoing share buy-back program, launched on February 17, 2026, to repurchase up to 342,130 shares for a maximum of DKK 725 million to meet obligations under its Restricted Stock Unit scheme. Between March 2 and March 6, 2026, the biotech group bought 101,000 shares for DKK 180.7 million, bringing total purchases under the program to 249,000 shares at a cost of DKK 452.6 million.
The company also corrected a previously reported figure, clarifying that accumulated purchases through March 2, 2026, were 63,000 shares rather than 1,431,958, resulting in a revised accumulated total of 148,000 shares prior to the latest transactions. Following these buy-backs, Genmab now holds 2,766,533 treasury shares, equal to 4.31% of its share capital and voting rights, with the program expected to be completed by March 31, 2026 in compliance with EU market abuse and safe harbour regulations.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen with operations across North America, Europe and Asia Pacific, it has built a broad portfolio of antibody-based formats, powering eight approved therapies and a late-stage clinical pipeline.
Average Trading Volume: 1,766,362
Technical Sentiment Signal: Sell
Current Market Cap: $16.42B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.